THOUSAND OAKS, Calif.,
Sept. 29, 2021 /PRNewswire/
-- Amgen (NASDAQ:AMGN) will host a webcast call for the
investment community in conjunction with the European Academy of
Dermatology and Venereology (EADV) 2021 Congress. On Monday,
Oct. 4, 2021, at 8:30 a.m. ET, David M. Reese, M.D., executive vice president
of Research and Development at Amgen, along with other members
of Amgen's management team, will discuss clinical data being
presented at EADV, including data from the AMG 451/KHK4083 Phase 2
trial in patients with moderate-to-severe atopic dermatitis, as
well as our broader inflammation portfolio.
Live audio of the investor call will be broadcast over the
internet simultaneously and will be available to members of the
news media, investors and the general public.
The webcast, as with other selected presentations regarding
developments in Amgen's business given at certain investor and
medical conferences, can be accessed on Amgen's website,
www.amgen.com, under Investors. Information regarding presentation
times, webcast availability and webcast links are noted on Amgen's
Investor Relations Events Calendar. The webcast will be archived
and available for replay for at least 90 days after the
event.
About Amgen
Amgen is committed to unlocking the
potential of biology for patients suffering from serious illnesses
by discovering, developing, manufacturing and delivering innovative
human therapeutics. This approach begins by using tools like
advanced human genetics to unravel the complexities of disease and
understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages
its expertise to strive for solutions that improve health outcomes
and dramatically improve people's lives. A biotechnology pioneer
since 1980, Amgen has grown to be one of the world's leading
independent biotechnology companies, has reached millions of
patients around the world and is developing a pipeline of medicines
with breakaway potential.
For more information, visit www.amgen.com and follow
us on www.twitter.com/amgen.
CONTACT: Amgen, Thousand
Oaks
Michael Strapazon, 805-313-5553
(media)
Trish Rowland,
805-447-5631(media)
Arvind Sood, 805-447-1060
(investors)
View original content to download
multimedia:https://www.prnewswire.com/news-releases/amgen-to-webcast-investor-call-at-eadv-2021-301388248.html
SOURCE Amgen